Valuation : AstraZeneca PLC

Market Cap 246B 212B 200B 182B 341B 23,461B 342B 2,379B 915B 11,936B 922B 902B 37,717B P/E 2026 *
20.3x
P/E 2027 * 17.7x
Enterprise Value 265B 228B 216B 196B 368B 25,319B 370B 2,568B 987B 12,881B 995B 973B 40,704B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 3.85x
Free-Float
96.63%
Yield 2026 *
2.11%
Yield 2027 * 2.25%
1 day+0.71%
1 week-2.03%
Current month-2.97%
1 month-0.51%
3 months-12.79%
6 months-18.02%
Current year-13.20%
1 week 134.6
Extreme 134.6
142.3
1 month 134
Extreme 134
147.45
Current year 134
Extreme 134
180.45
1 year 125
Extreme 125
180.45
3 years 112.45
Extreme 112.45
180.45
5 years 94.11
Extreme 94.11
180.45
10 years 47.74
Extreme 47.74
180.45
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%-2.03% - - 247B
-0.65%-2.93%+47.52%+87.34% 1,001B
-0.29%-3.51%+48.78%+63.27% 642B
+0.83%+0.26%+16.76%+72.52% 451B
-0.38%-3.45%+29.35%+34.09% 340B
-0.09%-14.68%+11.22%+27.14% 263B
-0.43%-3.61%-1.73%+7.95% 247B
-1.34%-13.70%+33.47%+44.18% 207B
-3.44%-8.32%-21.27%-59.20% 197B
-0.75%-4.82%+21.94%+86.55% 180B
Average -0.53%-5.53%+20.67%+40.43% 391.82B
Weighted average by Cap. -0.35%-4.65%+29.95%+55.13%

Financials

2026 *2027 *
Net sales 63.3B 54.54B 51.64B 46.81B 87.81B 6,047B 88.26B 613B 236B 3,077B 238B 233B 9,722B 66.9B 57.64B 54.58B 49.47B 92.81B 6,391B 93.28B 648B 249B 3,252B 251B 246B 10,275B
Net income 12.03B 10.36B 9.81B 8.89B 16.68B 1,149B 16.77B 117B 44.81B 585B 45.17B 44.17B 1,847B 13.77B 11.86B 11.23B 10.18B 19.1B 1,315B 19.2B 133B 51.3B 669B 51.7B 50.57B 2,114B
Net Debt 19.45B 16.76B 15.87B 14.38B 26.98B 1,858B 27.12B 188B 72.47B 945B 73.05B 71.44B 2,987B 11.77B 10.14B 9.6B 8.7B 16.32B 1,124B 16.41B 114B 43.84B 572B 44.19B 43.22B 1,807B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-09-11 137.40 +0.18% 547
26-09-10 €137.15 +0.26% 1,175
26-09-09 €136.80 -0.87% 428
26-09-08 €138.00 -1.92% 620
26-09-07 €140.70 +0.32% 4,163
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
159.06USD
Average target price
212.30USD
Spread / Average Target
+33.47%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!